Quarterly ResultMay 6, 2026, 04:09 PM
MannKind Q1 Revenue $90.2M, Net Loss $(16.6)M; Key PDUFA Dates Ahead
AI Summary
MannKind Corporation reported first-quarter 2026 total revenues of $90.2 million, a 15% increase year-over-year, driven by higher royalties and Furoscix sales. However, the company posted a net loss of $16.6 million, compared to a net income of $13.2 million in Q1 2025, due to significantly increased operating expenses related to Furoscix integration and pipeline advancement. The company highlighted upcoming PDUFA dates for Afrezza pediatric indication (May 29, 2026) and Furoscix ReadyFlow Autoinjector (July 26, 2026), alongside progress in its development pipeline and an expanded collaboration with United Therapeutics for ralinepag DPI.
Key Highlights
- Q1 2026 total revenues increased 15% to $90.2 million compared to Q1 2025.
- Reported a net loss of $16.6 million, or $(0.05) per share, compared to net income of $13.2 million, or $0.04 per share, in Q1 2025.
- Furoscix net sales were $15.5 million, with doses dispensed up 64% over Q1 2025.
- Afrezza net sales reached $15.3 million.
- Royalties increased 9% to $32.7 million, primarily from Tyvaso DPI sales.
- Afrezza pediatric indication PDUFA date is May 29, 2026; Furoscix ReadyFlow Autoinjector PDUFA date is July 26, 2026.
- Settled $36.3 million in senior convertible notes for $35.5 million cash and 569,023 shares.
- Cash, cash equivalents, and investments totaled $134 million as of March 31, 2026.
Price Impact
More from MNKD